{
    "nctId": "NCT02347449",
    "briefTitle": "The Impact of the Oncotype DX\u00ae Breast Cancer Assay on Treatment Decisions in a Canadian Population",
    "officialTitle": "The Impact of the Oncotype DX\u00ae Breast Cancer Assay on Treatment Decisions in a Canadian Population of Patients With Estrogen Receptor- Positive Early Breast Cancer With 1-3 Positive Lymph Nodes",
    "overallStatus": "COMPLETED",
    "conditions": "Hormone Receptor Positive Malignant Neoplasm of Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Change in physicians' treatment recommendations",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have undergone surgical treatment for breast cancer with adequate evaluation of lymph node status with a sentinel lymph node procedure or full axillary dissection, with positive involvement of 1-3 axillary lymph nodes as confirmed by histologic examination.\n* ECOG performance status 0 or 1\n* Patient must be a candidate for treatment of their cancer with systemic chemotherapy in addition to hormonal therapy\n* Eligible Staging Criteria: T1-3 N1 M0\n* Breast tumor must undergo central pathology review at GHI and must be found adequate for the Oncotype DX assay.\n* Breast tumor must be estrogen-receptor positive and HER2 positive (IHC/FISH) as per institutional guidelines\n\nExclusion Criteria:\n\n* Patient has a prior history of breast cancer in the same breast\n* Patient as been newly diagnosed with more than one operable primary breast tumor\n* Patient has multi-centric tumors (note: patients with multi-focal tumors may be included)\n* Patient has known metastatic breast cancer\n* Patient has \\<2mm invasive tumor as assessed by local pathologist\n* Patient has received any kind of neoadjuvant treatment\n* Presence of clinical factors rendering the patient a non-viable candidate for adjuvant chemotherapy\n* Presence of a current medical condition that would interfere with patient's ability to consent and participate in this study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}